Skip to main content
Caplight Logo









26 Therapeutics Inc.

26 Therapeutics Inc.

Private
MontrealHealthcare & Life Scienceshttps://www.26therapeutics.com/

Last Round

Pre Seed

Mar 4, 2026

Company Overview

26 Therapeutics Inc. is a biotechnology company developing first-in-class topical small-molecule therapies for dry eye disease and meibomian gland disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydry eye diseasemeibomian gland dysfunctionMGDsmall-molecule therapyCYP26B1 inhibitordrug discoveryophthalmologyocular surface healthpreclinical biotechbiotech startupevaporative dry eyetopical therapeuticseye care innovationbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

26 Therapeutics Inc. Comparables

Compare 26 Therapeutics Inc. with similar companies based on industry and business-model similarity.

26 Therapeutics Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OtusOphta Ltd.
79%
Novaliq
76%
Stuart Therapeutics, Inc.
76%

26 Therapeutics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedMar 4, 2026

26 Therapeutics Inc. Investors

Notable investors and investment history

26 Therapeutics Inc. investors
InvestorRounds
adMare BioInnovationsPre Seed

26 Therapeutics Inc. Filings

Explore SEC and related filing metadata, where available.

26 Therapeutics Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about 26 Therapeutics Inc.'s valuation, stock price, and market status.

Is 26 Therapeutics Inc. a public or private company?

26 Therapeutics Inc. is a private company.

What is the current stock price of 26 Therapeutics Inc.?

26 Therapeutics Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is 26 Therapeutics Inc. worth (valuation)?

Valuation information for 26 Therapeutics Inc. is not publicly available.

Can I buy 26 Therapeutics Inc. stock?

26 Therapeutics Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was 26 Therapeutics Inc.'s last funding round?

26 Therapeutics Inc.'s most recent funding round was Pre Seed on March 4, 2026.

Who are the main investors in 26 Therapeutics Inc.?

Key investors in 26 Therapeutics Inc. include adMare BioInnovations.

Will 26 Therapeutics Inc. IPO soon?

No public IPO plans have been announced for 26 Therapeutics Inc..

How can I track 26 Therapeutics Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor 26 Therapeutics Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMontreal
Employee Range2
Year Founded2026
Last FundingMar 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?